US Myocardial Infarction Market to Reach $5.8 Billion by 2035

US myocardial infarction market was valued at $3.3 billion in 2025 and is projected to reach $5.8 billion by 2035, registering a CAGR of 5.8% during the forecast period. Market growth is primarily driven by the rising prevalence of cardiovascular diseases, continuous advancements in interventional cardiology devices, and the increasing adoption of advanced diagnostic technologies. The growing preference for minimally invasive procedures, along with the expanding use of long-term pharmacological therapies, is further supporting market expansion. In addition, improvements in healthcare infrastructure and the strengthening of emergency cardiac care systems are contributing significantly to revenue growth across various treatment segments.

Browse the full report description of “US Myocardial Infarction Market Size, Share & Trends Analysis Report by Treatment Type (Pharmacological Treatment, Interventional Treatment, Diagnostics), by Device Type (Coronary Stents, Catheters & Guidewires, Thrombectomy Devices, Imaging Catheters (IVUS, OCT)), by End-User (Hospitals, Cardiac Care Centers / Cath Labs, Emergency Medical Services (EMS)), and Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/us-myocardial-infarction-market

A key macroeconomic driver of this market is the escalating burden of cardiovascular diseases in the United States. According to the American Heart Association, heart disease remains the leading cause of death in the country, largely due to increasing risk factors such as hypertension, obesity, and diabetes. Cardiovascular diseases accounted for over 941,000 deaths in 2022, indicating a rapidly expanding patient population. This growing disease burden is expected to drive higher demand for myocardial infarction diagnosis, treatment, and management solutions. Consequently, the increasing patient pool is fueling demand for interventional procedures, diagnostic testing, and post-myocardial infarction pharmacological therapies, thereby accelerating overall market growth.

Innovation Leaders Transforming the US Myocardial Infarction Market

The key players in the US myocardial infarction market include top companies such as Cardinal Health, Johnson & Johnson, Roche, Pfizer, and Merck & Co., among others. The market is witnessing steady expansion due to increasing adoption of minimally invasive coronary procedures and the rising use of combination drug therapies for post-MI management. Hospitals continue to dominate revenue generation, supported by high emergency admission rates and procedural volumes. Additionally, technological advancements in imaging-assisted PCI and biomarker-based diagnostics are improving treatment precision and patient outcomes.

• In March 2026, Medtronic announced support for the EMBRACE clinical trial targeting high cardiovascular-risk patients undergoing PCI. The study evaluates the use of renal denervation alongside PCI to reduce major adverse events, including myocardial infarction. The trial will include sites in the United States and aims to improve outcomes in patients with coronary artery disease and uncontrolled hypertension.
• In August 2025, Boston Scientific announced the initiation of patient enrollment in the EVOLVE clinical trial to evaluate its SYNERGY drug-eluting coronary stent. The study focuses on assessing safety and effectiveness in treating coronary artery lesions, with endpoints including myocardial infarction and revascularization outcomes.
• In March 2025, Abbott received FDA approval to initiate the TECTONIC clinical trial for its investigational Coronary Intravascular Lithotripsy (IVL) system in the US The study will enroll up to 335 patients across 47 sites to evaluate treatment of severely calcified coronary arteries before stenting. This technology uses sound pressure waves to break calcium blockages, potentially improving PCI outcomes and stent placement effectiveness.

Market Coverage

• The market number available for – 2025–2035
• Base year- 2025
• Forecast period- 2026–2035
• Segment Covered-
• By Treatment Type
• By Device Type
• By End-User
• Competitive Landscape: Cardinal Health, Johnson & Johnson, Roche, Pfizer, and Merck & Co., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

US Myocardial Infarction Market Report Segment

By Treatment Type

• Pharmacological Treatment
• Interventional Treatment
• Diagnostics

By Device Type

• Coronary Stents
• Catheters & Guidewires
• Thrombectomy Devices
• Imaging Catheters (IVUS, OCT)

By End-User

• Hospitals
• Cardiac Care Centers / Cath Labs
• Emergency Medical Services (EMS)

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/us-myocardial-infarction-market